StreetInsider.com News Articles

Ultragenyx Pharma (RARE) PT Lowered to $19 at Goldman Sachs

Fri, 04 Sep 2026 06:38:11 -0400

Goldman Sachs analyst Salveen Richter lowered the price target on Ultragenyx Pharma (NASDAQ: RARE) to $19.00 (from $28.00) while maintaining a Neutral rating.

Ultragenyx Pharma (RARE) PT Lowered to $32 at Barclays

Fri, 04 Sep 2026 04:22:42 -0400

Barclays analyst Eliana Merle lowered the price target on Ultragenyx Pharma (NASDAQ: RARE) to $32.00 (from $43.00) while maintaining a Overweight rating.

Morgan Stanley Downgrades Ultragenyx Pharma (RARE) to Equalweight

Thu, 03 Sep 2026 13:05:21 -0400

Morgan Stanley analyst Maxwell Skor downgraded Ultragenyx Pharma (NASDAQ: RARE) from Overweight to Equalweight with a price target of $18.00 (from $74.00).

For an analyst ratings summary and ratings history on Ultragenyx Pharma click here. For more ratings news on Ultragenyx Pharma click here.

Shares of Ultragenyx Pharma closed at $26.53 yesterday.

Increasing unusual call volume: GPRO XP RARE CHPT WSC WOOF CBRL DPRO KHC BNTX SBLK TSLT CPB

Thu, 03 Sep 2026 09:44:53 -0400

Increasing unusual call volume: GPRO XP RARE CHPT WSC WOOF CBRL DPRO KHC BNTX SBLK TSLT CPB

BofA Securities Downgrades Ultragenyx Pharma (RARE) to Neutral

Thu, 03 Sep 2026 09:40:35 -0400

BofA Securities analyst Tazeen Ahmad downgraded Ultragenyx Pharma (NASDAQ: RARE) from Buy to Neutral with a price target of $20.00 (from $48.00).

For an analyst ratings summary and ratings history on Ultragenyx Pharma click here. For more ratings news on Ultragenyx Pharma click here.

Shares of Ultragenyx Pharma closed at $26.53 yesterday.

Ultragenyx Pharma (RARE) PT Lowered to $18 at TD Cowen

Thu, 03 Sep 2026 08:05:24 -0400

TD Cowen analyst Yaron Werber lowered the price target on Ultragenyx Pharma (NASDAQ: RARE) to $18.00 (from $49.00) while maintaining a Buy rating.

RBC Capital Downgrades Ultragenyx Pharma (RARE) to Sector Perform

Thu, 03 Sep 2026 07:28:42 -0400

RBC Capital analyst Luca Issi downgraded Ultragenyx Pharma (NASDAQ: RARE) from Outperform to Sector Perform with a price target of $19.00.

For an analyst ratings summary and ratings history on Ultragenyx Pharma click here. For more ratings news on Ultragenyx Pharma click here.

Shares of Ultragenyx Pharma closed at $26.53 yesterday.

Ultragenyx Pharma (RARE) PT Lowered to $25 at H.C. Wainwright

Thu, 03 Sep 2026 06:54:51 -0400

(Updated - September 3, 2026 6:54 AM EDT)

H.C. Wainwright analyst Ed Arce lowered the price target on Ultragenyx Pharma (NASDAQ: RARE) to $25.00 (from $50.00) while maintaining a Buy rating.

The analyst commented: "Yesterday, Ultragenyx announced results from the Phase 3 Aspire study for apazunersen (GTX-102) in Angelman syndrome. The study did not achieve the primary endpoint of change from Baseline in Bayley-4 cognitive raw score nor the key secondary endpoint of net response in Multidomain Responder Index (MDRI). The safety profile observed in Aspire was consistent with Phase 1/2 data. In Aspire, the randomized groups were comparable at baseline and

Ultragenyx Pharma (RARE) PT Lowered to $25 at H.C. Wainwright

Thu, 03 Sep 2026 06:54:51 -0400

(Updated - September 3, 2026 6:54 AM EDT)

H.C. Wainwright analyst Ed Arce lowered the price target on Ultragenyx Pharma (NASDAQ: RARE) to $25.00 (from $50.00) while maintaining a Buy rating.

Ultragenyx Pharma (RARE) PT Lowered to $37 at Canaccord

Thu, 03 Sep 2026 06:52:49 -0400

(Updated - September 3, 2026 6:52 AM EDT)

Canaccord analyst Whitney Ijem lowered the price target on Ultragenyx Pharma (NASDAQ: RARE) to $37.00 (from $83.00) while maintaining a Buy rating.

The analyst commented: "After the close, RARE announced that the Ph3 Aspire study of GTX-102 (apazunersen) in Angelman syndrome missed both the primary endpoint of change from baseline in Bayley-4 cognitive raw score and the key secondary endpoint of net response on the MDRI. The PR noted that “There were no differences between the treated and control groups that could support efficacy in the Bayley Cognition raw scores nor in the MDRI

Ultragenyx Pharma (RARE) PT Lowered to $37 at Canaccord

Thu, 03 Sep 2026 06:52:49 -0400

(Updated - September 3, 2026 6:52 AM EDT)

Canaccord analyst Whitney Ijem lowered the price target on Ultragenyx Pharma (NASDAQ: RARE) to $37.00 (from $83.00) while maintaining a Buy rating.

Ultragenyx Pharma (RARE) PT Lowered to $37 at Canaccord

Thu, 03 Sep 2026 06:52:49 -0400

(Updated - September 3, 2026 6:52 AM EDT)

Canaccord analyst Whitney Ijem lowered the price target on Ultragenyx Pharma (NASDAQ: RARE) to $37.00 (from $83.00) while maintaining a Buy rating.

Ultragenyx Pharma (RARE) PT Lowered to $33 at Cantor Fitzgerald

Thu, 03 Sep 2026 06:35:44 -0400

Cantor Fitzgerald analyst Kristen Kluska lowered the price target on Ultragenyx Pharma (NASDAQ: RARE) to $33.00 (from $103.00) while maintaining a Overweight rating.

The analyst comments "● We believe RARE truly has to lower its spend substantially for investors to want to even consider building a position with the recent setbacks. ● This will be absolutely instrumental for getting investors to focus on the true value of the commercial business. Ultragenyx noted in its release that it will assess planned operations to define and implement significant expense reductions. ● We lower our PT to $33 from $103 by removing GTX-102 from

Premarket movers: Snowflake, Five Below surge after strong earnings

Thu, 03 Sep 2026 06:32:01 -0400

Investing.com -- U.S. equity futures were mixed early Thursday, a day after major averages snapped a three-day losing streak driven by rising Treasury yields amid renewed U.S.-Iran hostilities. S&P 500 futures were up 0.1%, Dow futures rose 0.2%, and Nasdaq 100 futures climbed 0.1%.

Among individual stocks, Snowflake shares jumped more than 23% in premarket trading after the company posted second-quarter results that topped expectations and raised its full-year outlook. Adjusted earnings came in at 62 cents a share, beating estimates of 45 cents, while revenue rose 35% year-over-year to $1.55 billion. Product revenue climbed 37% to $1.49 billion, marking a third

Premarket movers: Snowflake, Five Below surge after strong earnings

Thu, 03 Sep 2026 06:32:01 -0400

Premarket movers: Snowflake, Five Below surge after strong earnings

Thu, 03 Sep 2026 06:32:01 -0400

Ultragenyx Pharma (RARE) PT Lowered to $18 at Wells Fargo, Downgrades to Equalweight

Thu, 03 Sep 2026 06:22:36 -0400

Wells Fargo analyst Ben Burnett lowered the price target on Ultragenyx Pharma (NASDAQ: RARE) to $18.00 (from $50.00) while downgrading to Equalweight (from Overweight).

The analyst comments "We are lowering our PT to $18 as a result of removing GTX-102 from our model. RARE announced that the ASPIRE trial did not achieve the primary endpoint of Bayley-4 cognitive raw score nor the key secondary endpoint of MDRI. Additionally, there were no pos. trends on subscales. We see the setback as a neg. for the PoS of the AURORA, which we think is more risky as this trial includes mutation patients. Removing

Ultragenyx Pharma (RARE) PT Lowered to $18 at Wells Fargo, Downgrades to Equalweight

Thu, 03 Sep 2026 06:22:36 -0400

Wells Fargo analyst Ben Burnett lowered the price target on Ultragenyx Pharma (NASDAQ: RARE) to $18.00 (from $50.00) while downgrading to Equalweight (from Overweight).

Ultragenyx Pharma (RARE) PT Lowered to $18 at Wells Fargo, Downgrades to Equalweight

Thu, 03 Sep 2026 06:22:36 -0400

Wells Fargo analyst Ben Burnett lowered the price target on Ultragenyx Pharma (NASDAQ: RARE) to $18.00 (from $50.00) while downgrading to Equalweight (from Overweight).

Ultragenyx Pharma (RARE) call put ratio 1 call to 3 puts into Phase 3 results

Thu, 03 Sep 2026 06:01:25 -0400

Ultragenyx Pharma (NASDAQ: RARE) 30-day option implied volatility is at 170; compared to its 52-week range of 40 to 182. Call put ratio 1 call to 3 puts into Phase 3 results.

JPMorgan Downgrades Ultragenyx Pharma (RARE) to Neutral

Thu, 03 Sep 2026 04:10:47 -0400

JPMorgan analyst Anupam Rama downgraded Ultragenyx Pharma (NASDAQ: RARE) from Overweight to Neutral with a price target of $36.00 (from $80.00).

The analyst comments: “We are downgrading Ultragenyx (RARE shares) to a Neutral rating following the setback in the Phase 3 ASPIRE trial of GTX-102 for the treatment of Angelman Syndrome. We are also decreasing our December 2027 price target to $36 from $80.

Overall, we see fundamental value in the commercial business, which we value in the mid-$20s/share range. This includes probability-adjusted revenue from UX111 in MPS IIIA, for which we see a high likelihood of approval heading into the PDUFA

JPMorgan Downgrades Ultragenyx Pharma (RARE) to Neutral

Thu, 03 Sep 2026 04:10:47 -0400

JPMorgan analyst Anupam Rama downgraded Ultragenyx Pharma (NASDAQ: RARE) from Overweight to Neutral with a price target of $36.00 (from $80.00).

Baird Downgrades Ultragenyx Pharma (RARE) to Neutral

Thu, 03 Sep 2026 04:09:24 -0400

Baird analyst Joel Beatty downgraded Ultragenyx Pharma (NASDAQ: RARE) from Outperform to Neutral with a price target of $16.00 (from $40.00).

The analyst comments: “After the close, Ultragenyx announced the pivotal Phase 3 Aspire study of GTX-102 in Angelman syndrome failed to hit either of the key endpoints (Bayley-4 cognitive raw score and MDRI). Disappointingly, given the miss on both endpoints, we suspect this trial was a complete whiff. Given this context, we're reducing our price target to $16/share and downgrading to Neutral as we anticipate investor interest in the story will be limited given unknowns surrounding Crysvita's commercial longevity and

Baird Downgrades Ultragenyx Pharma (RARE) to Neutral

Thu, 03 Sep 2026 04:09:24 -0400

Baird analyst Joel Beatty downgraded Ultragenyx Pharma (NASDAQ: RARE) from Outperform to Neutral with a price target of $16.00 (from $40.00).

Evercore ISI Downgrades Ultragenyx Pharma (RARE) to In Line

Thu, 03 Sep 2026 02:36:31 -0400

Evercore ISI analyst Gavin Clark-Gartner downgraded Ultragenyx Pharma (NASDAQ: RARE) from Outperform to In Line with a price target of $16.00 (from $34.00).

The analyst comments: “Angelman is a huge unmet need so would’ve been great for the community if ‘102 succeeded. Unfortunately sounds like a clean fail. Always a risky study and stock is roughly trading as expected (our last note).

We’ve updated our model and new PT = $16/sh from $34 prev ($1.7 mkt cap; we est. ~$525M YE26 cash post PRV sales).

Given the heavy expense burden, Crysvita LOE ~10yrs out, and growth reliance on first gen AAV8/9 systemic GTx